Načítá se...
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in “LD phobia”...
Uloženo v:
| Vydáno v: | Curr Neuropharmacol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Bentham Science Publishers
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876591/ https://ncbi.nlm.nih.gov/pubmed/26644151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X14666151208114634 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|